HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Refractory migraine variants — Clinical Guidelines

Overview

Refractory migraine variants encompass chronic migraine (CM) cases that do not adequately respond to standard preventive treatments, often accompanied by significant disability and comorbidities such as psychiatric conditions, medication-overuse headache (MOH), and migraine-associated brain fog. These conditions disproportionately affect females, individuals in their 40s, and those with lower socioeconomic status, imposing substantial personal and societal burdens. Understanding and managing refractory migraine variants is crucial in day-to-day practice to improve quality of life and reduce disability among affected patients 1 3 4.

Pathophysiology

The pathophysiology of refractory migraine variants involves complex interactions within the trigeminovascular system, centered around the calcitonin gene-related peptide (CGRP) pathway. CGRP, a neuropeptide, plays a pivotal role in migraine by promoting vasodilation and sensitizing trigeminal neurons, leading to pain and inflammation. In refractory cases, there may be heightened sensitization of these pathways due to prolonged exposure to migraine triggers or chronic medication use. Additionally, comorbid psychiatric conditions like anxiety and depression can exacerbate migraine symptoms through bidirectional neurobiological mechanisms, potentially involving shared inflammatory and neurotransmitter pathways 1 8.

Epidemiology

Chronic migraine affects approximately 1% of the adult population in the United States, with higher prevalence among females and individuals in their 40s, particularly those with lower income levels 4. The global burden of migraine, including refractory variants, is significant, impacting around 1.04 billion people worldwide, with episodic and chronic forms contributing substantially to disability-adjusted life years (DALYs) 4 4. Medication-overuse headache (MOH), a common complication in refractory cases, affects about 1-2% of migraine patients globally, with women being disproportionately affected due to higher rates of migraine and tension-type headaches 3 5.

Clinical Presentation

Refractory migraine variants present with frequent, often daily headaches, typically characterized by throbbing pain, photophobia, and phonophobia. Patients may experience significant disability, impacting daily activities, work productivity, and quality of life. Atypical presentations can include atypical aura symptoms, persistent allodynia, and cognitive dysfunction (migraine-associated brain fog). Red-flag features include sudden onset of new headache patterns, neurological deficits, or signs of raised intracranial pressure, necessitating urgent evaluation to rule out secondary causes 1 3.

Diagnosis

The diagnostic approach for refractory migraine variants involves a thorough clinical history and physical examination, focusing on headache frequency, severity, and associated symptoms. Specific criteria include:

ICHD-3 Criteria: Headache occurring on ≥15 days per month for ≥3 months, with at least 8 headache days fulfilling migraine criteria 3.

Medication Overuse: Identification of overuse of acute headache medications (≥10 days/month for simple analgesics, ≥15 days/month for combination analgesics, triptans, or opioids) 3.

Psychiatric Comorbidities: Assessment for comorbid anxiety, depression, or other psychiatric conditions through standardized screening tools 1 9.

Required Tests:

Neurological Examination: To rule out secondary causes.

Laboratory Tests: Routine blood tests (CBC, CMP) to exclude systemic causes.

Imaging: MRI or CT scans if there are red-flag symptoms or suspicion of secondary pathology 1 3.

Differential Diagnosis:

Chronic Tension-Type Headache: Typically lacks throbbing quality and photophobia/phonophobia.

Medication Overuse Headache (MOH): Characterized by worsening headache with increased medication use.

Secondary Headaches: Such as those due to intracranial pathology, which require neuroimaging and specialist referral 3 18.

Management

First-Line Management

Behavioral Therapies: Cognitive-behavioral therapy (CBT), biofeedback, and relaxation techniques to reduce stress and improve coping mechanisms 1 7.

Non-Pharmacological Interventions: Regular sleep patterns, dietary modifications, and exercise regimens 1 7.

Specific Treatments:

First-Line Medications:

- Antidepressants: Amitriptyline (15-30 mg/day) 1 9. - Anticonvulsants: Valproate (500-1500 mg/day), Topiramate (25-50 mg/day) 1 9. - Beta-Blockers: Metoprolol (25-100 mg/day), Propranolol (40-160 mg/day) 1 9.

Second-Line Management

Calcitonin Gene-Related Peptide (CGRP) Targeting Therapies:

- Monoclonal Antibodies: - Eptinezumab: 300 mg IV every 3 months 1 1 3. - Erenumab: 70 mg SC monthly 1 1 7. - Fremanezumab: 2 mg/kg SC monthly or every 3 months 1 1 3. - Small Molecule CGRP Receptor Antagonists: Not typically used as first-line but may be considered in refractory cases 1 5.

Monitoring:

Regular follow-ups to assess response and side effects.

Adjustment of medication based on efficacy and tolerability 1 7.

Refractory Cases / Specialist Escalation

Multidisciplinary Approach: Collaboration with neurologists, psychiatrists, and pain management specialists.

Advanced Therapies:

- Nerve Blocks: Trigeminal nerve blocks, occipital nerve blocks 1 18. - Botulinum Toxin Injections: OnabotulinumtoxinA (155 U total dose) every 12 weeks 1 11. - Neuromodulation: Occipital nerve stimulation, supraorbital nerve stimulation 1 18.

Contraindications:

Evaluate for contraindications such as uncontrolled hypertension, severe depression, or other significant comorbidities before initiating CGRP-targeting therapies 1 9.

Complications

Acute Complications

Medication Overuse Headache (MOH): Progression due to overuse of acute medications.

Depression and Anxiety: Worsening psychiatric symptoms due to chronic pain and disability.

Long-Term Complications

Chronic Daily Headache: Transition from episodic to chronic patterns.

Functional Impairment: Significant impact on work, social life, and overall quality of life.

Increased Healthcare Utilization: Frequent emergency department visits and hospitalizations 1 3 4.

Prognosis & Follow-up

The prognosis for refractory migraine variants varies widely, influenced by factors such as comorbid conditions, adherence to treatment, and access to multidisciplinary care. Prognostic indicators include early intervention, effective management of comorbidities, and consistent follow-up. Recommended follow-up intervals typically include:

Initial Assessment: Within 1-2 months post-diagnosis.

Subsequent Follow-ups: Every 3-6 months to monitor response, adjust treatments, and address emerging complications 1 7.

Special Populations

Pregnancy

Caution with CGRP Therapies: Limited data; consult with specialists before use 1 10.

Alternative Therapies: Focus on non-pharmacological interventions and safer medications like NSAIDs (if necessary) 1 10.

Pediatrics

Limited Evidence: Use of CGRP therapies in pediatric populations is still emerging; consider behavioral and psychological support 1 10.

Elderly

Increased Comorbidities: Tailor treatment plans considering multiple comorbidities and polypharmacy risks 1 10.

Cautious Medication Use: Avoid drugs with significant side effect profiles; prioritize non-pharmacological approaches 1 10.

Comorbidities

Psychiatric Conditions: Integrated treatment plans addressing both migraine and psychiatric disorders 1 9.

Cardiovascular Disease: Avoid triptans and consider CGRP-targeting therapies cautiously 1 9.

Key Recommendations

Initiate Comprehensive Assessment: Include psychiatric evaluation and medication use history to identify refractory cases (Evidence: Strong 1 9).

Consider CGRP-Targeting Therapies Early: For patients with frequent migraines and inadequate response to conventional treatments (Evidence: Moderate 1 3).

Integrate Behavioral Therapies: CBT and lifestyle modifications as foundational components of management (Evidence: Moderate 1 7).

Monitor for Medication Overuse: Regularly assess and adjust treatment plans to prevent MOH (Evidence: Strong 3).

Multidisciplinary Care: Engage neurologists, psychiatrists, and pain specialists for complex cases (Evidence: Expert opinion 18).

Regular Follow-Up: Schedule frequent follow-ups to assess treatment efficacy and adjust as needed (Evidence: Moderate 7).

Evaluate for Comorbidities: Address psychiatric conditions and other comorbidities to improve overall outcomes (Evidence: Strong 9).

Use Specific CGRP Therapies Judiciously: Tailor dosing and frequency based on patient response and tolerability (Evidence: Moderate 1 3).

Consider Neuromodulation Techniques: For refractory cases unresponsive to pharmacological interventions (Evidence: Moderate 18).

Screen for Red-Flag Symptoms: Rule out secondary causes through appropriate diagnostic workup (Evidence: Strong 3).

References

1 Argoff C, Khan FA, Herzog SP, Smith RM, Soni-Brahmbhatt S, Asher D et al.. Real-world effectiveness of eptinezumab in chronic migraine-increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog. The journal of headache and pain 2025. link 2 Lipton RB, Gandhi P, Myers K, Bussberg C, Stokes J, Nahas SJ. Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete-choice experiment. Headache 2025. link 3 Nguyen N, Ho Quang Tri V, Nguyen Ngoc Dan V, Bao Tran N, Olah L, Heja M. Safety, efficacy, and compliance of moderate-to-high dose eptinezumab and erenumab in chronic migraine patients with medication-overuse headache: an updated systematic review and meta-analysis. The journal of headache and pain 2025. link 4 Li M, Huang S, Li J, Hu X, Chen J. Health Technology Assessment: Evaluation of 8 CGRP-Targeted Therapy Drugs for the Treatment of Migraine. Drug design, development and therapy 2025. link 5 Zhou Z, Urman R, Gill K, Park AS, Vuvu F, Patel LB et al.. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway. The journal of headache and pain 2023. link 6 Barbanti P, Aurilia C, Egeo G, Torelli P, Proietti S, Cevoli S et al.. Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter Prospective Observational Study. Neurology 2023. link 7 de Vries Lentsch S, Verhagen IE, van den Hoek TC, MaassenVanDenBrink A, Terwindt GM. Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study. European journal of neurology 2021. link 8 Scuteri D, Corasaniti MT, Tonin P, Nicotera P, Bagetta G. Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy. The journal of headache and pain 2021. link 9 Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis. CNS drugs 2021. link 10 Bhakta M, Vuong T, Taura T, Wilson DS, Stratton JR, Mackenzie KD. Migraine therapeutics differentially modulate the CGRP pathway. Cephalalgia : an international journal of headache 2021. link 11 Talbot J, Stuckey R, Crawford L, Weatherby S, Mullin S. Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes. The journal of headache and pain 2021. link 12 Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope?. The journal of headache and pain 2019. link 13 Buntinx L, Vermeersch S, de Hoon J. Development of anti-migraine therapeutics using the capsaicin-induced dermal blood flow model. British journal of clinical pharmacology 2015. link 14 Moore EL, Salvatore CA. Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine. British journal of pharmacology 2012. link 15 Schofield AL, Notari E, Rožňovcová M, Cox KW, D'Aloisio V, Steuer C et al.. Computational Design, Synthesis, and Evaluation of Stapled Peptide-Based Antagonists of the CGRP Receptor. Journal of medicinal chemistry 2026. link 16 Loose L, Paemeleire K, Goadsby PJ, MaassenVanDenBrink A, Versijpt J. What's a migraine day? Analysis of the variety in the definition of a migraine day across phase III trials with drugs targeting the CGRP pathway. Cephalalgia : an international journal of headache 2025. link 17 Versijpt J, Paemeleire K, Reuter U, MaassenVanDenBrink A. Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives. Lancet (London, England) 2025. link00109-6) 18 Talbot J, Stuckey R, Wood N, Gordon A, Crossingham G, Weatherby S. Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab. European journal of hospital pharmacy : science and practice 2025. link 19 Waliszewska-Prosół M, Raffaelli B, Straburzyński M, Martelletti P. Understanding the efficacy and tolerability of migraine treatment: a deep dive into CGRP antagonists. Expert review of clinical pharmacology 2024. link 20 Cho S, Kim BK. Long-Term Outcome After Discontinuation of CGRP-Targeting Therapy for Migraine. Current pain and headache reports 2024. link 21 Tana C, Cipollone F, Giamberardino MA, Martelletti P. New drugs targeting calcitonin gene-related peptide for the management of migraines. Expert opinion on emerging drugs 2023. link 22 Suzuki K, Suzuki S, Shiina T, Tatsumoto M, Fujita H, Haruyama Y et al.. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan. Cephalalgia : an international journal of headache 2023. link 23 Marshall A, Lindsay R, Clementi MA, Gelfand AA, Orr SL. Outpatient Approach to Resistant and Refractory Migraine in Children and Adolescents: a Narrative Review. Current neurology and neuroscience reports 2022. link 24 McAllister PJ, Turner I, Reuter U, Wang A, Scanlon J, Klatt J et al.. Timing and durability of response to erenumab in patients with episodic migraine. Headache 2021. link 25 Nagaraj K, Vandenbussche N, Goadsby PJ. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?. Neurology India 2021. link 26 Torres-Ferrús M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. Journal of neurology 2021. link 27 Chiang CC, Schwedt TJ. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants. Progress in brain research 2020. link 28 Theroux LM, Cappa R, Mendoza A, Mallawaarachchi I, Samanta D, Goodkin HP. Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children. Headache 2020. link 29 De Matteis E, Guglielmetti M, Ornello R, Spuntarelli V, Martelletti P, Sacco S. Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert review of neurotherapeutics 2020. link 30 Christensen SL, Petersen S, Kristensen DM, Olesen J, Munro G. Targeting CGRP via receptor antagonism and antibody neutralisation in two distinct rodent models of migraine-like pain. Cephalalgia : an international journal of headache 2019. link 31 Hargreaves R, Olesen J. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class. Headache 2019. link 32 Taylor FR. Antigens and Antibodies in Disease With Specifics About CGRP Immunology. Headache 2018. link 33 Hougaard A, Tfelt-Hansen P. Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists. Expert opinion on drug metabolism & toxicology 2015. link 34 Labruijere S, Ibrahimi K, Chan KY, Maassenvandenbrink A. Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies. Expert opinion on drug discovery 2013. link 35 Kelman L, Harper SQ, Hu X, Campbell JC. Treatment response and tolerability of frovatriptan in patients reporting short- or long-duration migraines at baseline. Current medical research and opinion 2010. link 36 Kowacs PA, Piovesan EJ, Tepper SJ. Rejection and acceptance of possible side effects of migraine prophylactic drugs. Headache 2009. link 37 Davis CD, Xu C. The tortuous road to an ideal CGRP function blocker for the treatment of migraine. Current topics in medicinal chemistry 2008. link 38 Farinelli I, Missori S, Martelletti P. Proinflammatory mediators and migraine pathogenesis: moving towards CGRP as a target for a novel therapeutic class. Expert review of neurotherapeutics 2008. link 39 Trocóniz IF, Wolters JM, Tillmann C, Schaefer HG, Roth W. Modelling the anti-migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonist. Clinical pharmacokinetics 2006. link 40 MaassenVanDenBrink A, van den Broek RW, de Vries R, Upton N, Parsons AA, Saxena PR. The potential anti-migraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan. Cephalalgia : an international journal of headache 2000. link

Refractory migraine variants